[go: up one dir, main page]

WO1996024345A3 - Uses of a vitamin of the k-group against a loss of cognitive faculties - Google Patents

Uses of a vitamin of the k-group against a loss of cognitive faculties Download PDF

Info

Publication number
WO1996024345A3
WO1996024345A3 PCT/DE1996/000183 DE9600183W WO9624345A3 WO 1996024345 A3 WO1996024345 A3 WO 1996024345A3 DE 9600183 W DE9600183 W DE 9600183W WO 9624345 A3 WO9624345 A3 WO 9624345A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
substance
group
blood
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1996/000183
Other languages
German (de)
French (fr)
Other versions
WO1996024345A2 (en
Inventor
Martin Kohlmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19504003A external-priority patent/DE19504003A1/en
Application filed by Individual filed Critical Individual
Priority to AU46186/96A priority Critical patent/AU4618696A/en
Priority to EP96901702A priority patent/EP0759748A1/en
Publication of WO1996024345A2 publication Critical patent/WO1996024345A2/en
Publication of WO1996024345A3 publication Critical patent/WO1996024345A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention concerns the novel use of a vitamin of the K group or a substance influencing the transport of a vitamin of the K group, or a substance activating the regeneration of a vitamin of the K group in order to produce a preparation which is active against an accelerated loss of cognitive faculties, in particular against the effects of Alzheimer's disease. In order to produce a preparation for assessing the risk of an accelerated loss of cognitive faculties or Alzheimer's disease occurring, the invention further proposes the use of a substance which can determine the concentration of vitamin K in the blood or other body fluids, the use of a substance which can determine the portion of carboxylated glutamate groups in vitamin K-dependent proteins in blood or other body fluids, and the use of a substance which can determine the concentration of η-carboxy glutamate in blood or other body fluids or in excretions.
PCT/DE1996/000183 1995-02-08 1996-02-07 Uses of a vitamin of the k-group against a loss of cognitive faculties Ceased WO1996024345A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU46186/96A AU4618696A (en) 1995-02-08 1996-02-07 Uses of a vitamin of the k-group against a loss of cognitive faculties
EP96901702A EP0759748A1 (en) 1995-02-08 1996-02-07 Uses of a vitamin of the k-group against a loss of cognitive faculties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19504003.1 1995-02-08
DE19504003A DE19504003A1 (en) 1995-02-08 1995-02-08 Treatment of cognitive disorders, esp. Alzheimer's disease

Publications (2)

Publication Number Publication Date
WO1996024345A2 WO1996024345A2 (en) 1996-08-15
WO1996024345A3 true WO1996024345A3 (en) 1997-02-20

Family

ID=7753374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/000183 Ceased WO1996024345A2 (en) 1995-02-08 1996-02-07 Uses of a vitamin of the k-group against a loss of cognitive faculties

Country Status (4)

Country Link
EP (1) EP0759748A1 (en)
AU (1) AU4618696A (en)
DE (1) DE19549262C2 (en)
WO (1) WO1996024345A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646429B (en) * 2007-04-05 2012-08-29 J-制油株式会社 Ataractic agent and functional food

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366480A2 (en) * 1988-10-27 1990-05-02 Bar Ilan University Method and compositions for treating Alzheimer's disease, related dementias & epilepsy
US5059627A (en) * 1989-08-24 1991-10-22 Takeda Chemical Industries, Ltd. Nerve growth factor secretion inducing composition
WO1991016047A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5h)-furanones as anti-inflammatory agents
JPH06340526A (en) * 1993-06-02 1994-12-13 Mitsui Toatsu Chem Inc Nerve growth factor production / secretion inducer containing a substituted 1,4-naphthoquinone derivative as an active ingredient
EP0629400A1 (en) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone compositions for treating Alzheimer's disease
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438208A (en) * 1982-05-27 1984-03-20 The Regents Of The University Of California Region-specific determinants for vitamin K dependent bone protein
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
FR2678638A1 (en) * 1991-07-03 1993-01-08 Inst Nat Sante Rech Med Polyclonal and monoclonal antibodies against the tau protein for the diagnosis of Alzheimer's disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366480A2 (en) * 1988-10-27 1990-05-02 Bar Ilan University Method and compositions for treating Alzheimer's disease, related dementias & epilepsy
US5059627A (en) * 1989-08-24 1991-10-22 Takeda Chemical Industries, Ltd. Nerve growth factor secretion inducing composition
WO1991016047A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5h)-furanones as anti-inflammatory agents
JPH06340526A (en) * 1993-06-02 1994-12-13 Mitsui Toatsu Chem Inc Nerve growth factor production / secretion inducer containing a substituted 1,4-naphthoquinone derivative as an active ingredient
EP0629400A1 (en) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone compositions for treating Alzheimer's disease
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9509, Derwent World Patents Index; AN 95-063774, XP002011185 *
M.J. SHEARER: "Vitamin K metabolism and nutriture", BLOOD REV., vol. 6, no. 2, 1992, pages 92 - 104, XP002011184 *
R.B. RUCKER ET AL.: "New perspectives on function of vitamins", NUTRITION, vol. 10, no. 6, 1994, pages 507 - 513, XP002011183 *

Also Published As

Publication number Publication date
WO1996024345A2 (en) 1996-08-15
DE19549262C2 (en) 1997-10-09
EP0759748A1 (en) 1997-03-05
DE19549262A1 (en) 1996-09-05
AU4618696A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
AR052921A1 (en) USE OF RANOLAZINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
DE68903516D1 (en) AGENT FOR REDUCING BLOOD PRESSURE.
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
WO1996019580A3 (en) Telomerase protein component
TR199700872A2 (en) Use of complex lipids.
EP1053315A4 (en) GENE OF CALVITIS IN MEN, PROTEIN AND USES THEREOF
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
EE9800066A (en) Use of erythropoietin and iron preparations for the preparation of a combined pharmaceutical preparation, combined pharmaceutical packaging and method for determining the iron status of a body fluid sample
WO1996024345A3 (en) Uses of a vitamin of the k-group against a loss of cognitive faculties
DK0821593T3 (en) Conjugate of an active agent, a protein and, optionally, a non-foreign native protein considered by the body
EP0373771A3 (en) New pharmaceutical uses for cystatins
ES2176523T3 (en) PROCEDURE FOR THE DETECTION OF ALZHEIMER'S DISEASE.
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
WO1998011246A3 (en) ENDO-β-GALACTOSIDASE
WO1996032133A3 (en) Conjugate for treating inflammatory, infectious and/or skin diseases
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
EP0778027A3 (en) Use of silica for the preparation of a medicament
FR2618439B1 (en) SEQUENCES OF AMINO ACIDS REPRODUCING AT LEAST IN PART THE SEQUENCE OF ANIMAL AND HUMAN LECTINS, THEIR PROCESSES FOR OBTAINING THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
Jones No more use for general anaesthesia
Castrogiovanni et al. Platelet phenol sulphotransferase: A peripheral marker of the dopamine system?
Gunderson et al. " Borderline personality disorder and depression": Reply.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1996901702

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1996901702

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996901702

Country of ref document: EP